Classical enzyme-replacement therapies (ERT) with recombinant glucocerebrosidase in Gaucher disease do not cross the BBB, nor do they affect neurological symptoms; thus, for PD treatment, these would require vector-mediated delivery (e.g., AAV) [78]. Here, GBA1 is linked to Gaucher disease.